Lycia Therapeutics Inc. (LYCA) vs Nurix Therapeutics, Inc. (NRIX)

Lycia Therapeutics Inc. LYCA 30.50 +5.90%
Nurix Therapeutics, Inc. NRIX 15.30 +3.10%

Lycia Therapeutics Inc. and Nurix Therapeutics, Inc. are both Biotechnology companies. Lycia Therapeutics Inc. and Nurix Therapeutics, Inc. are of similar size ($1.7B and $1.6B).

Metric	LYCA	NRIX	Biotechnology median
P/E	—	6.06	10.60
P/S	—	2.42	9.40
P/B	—	1.75	2.13
Price to free cash flow	—	4.59	25.18
EV/EBITDA	—	2.20	0.66
EV/Sales	—	0.92	9.02
Earnings yield	—	16.50%	(32.88%)
Free cash flow yield	—	21.79%	(23.13%)

Metric	LYCA	NRIX	Biotechnology median
Gross margin	—	100.00%	68.51%
Operating margin	—	41.27%	0.00%
Net margin	—	42.01%	0.00%
Free cash flow margin	—	52.68%	0.00%
Return on equity	—	43.99%	(51.96%)
Return on assets	—	34.33%	(46.06%)
Return on invested capital	—	0.00%	0.00%

Metric	LYCA	NRIX	Biotechnology median
Revenue growth (TTM)	—	738.76%	6.76%
EPS growth (last fiscal year)	—	(5.90%)	29.88%
Revenue growth, 5-year CAGR	—	36.35%	9.75%
Net income growth, 5-year CAGR	—	0.00%	0.00%

Metric	LYCA	NRIX	Biotechnology median
Debt to equity	—	0.00	0.00
Current ratio	—	8.44	4.97
Net debt to EBITDA	—	2.14	1.01

Metric	LYCA	NRIX	Biotechnology median
Dividend yield	—	—	0.41%
Payout ratio	—	—	—

Metric	LYCA	NRIX	Biotechnology median
Market cap	1.66b	1.62b	161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack